*Refresh the page if the below document does not appear.
Govt authority suspends license of firm for selling Breast milk
The Government terminated the license of this Punjab-based health-tech start-up named “Neslak Biosciences” over production and marketing of Human breast milk. The product named HapiNes which was a freeze-dried ready-to-use powder was violating the Food Safety and Standards Act 2006.
Gambia informs children deaths linked to cough syrups have risen to 70
Gambia Government is also investigating the case and is about to set up a new commission this week to dig deeper into it. The news was shared by the President of Gambia Adama Barrow in an emergency Cabinet meeting that took place on Thursday.
Prospects for digital health are limitless with proper implementation & coordination: NHA CEO
The Chief Executive Officer of the National Health Authority stated that the prospects of digital health are limitless only if the implementation is done with proper coordination of all stakeholders. He added that with digital health, healthcare can be made more accessible, effective, and time-saving.
Expert Commitee formed to investigate WHO's case on Maiden Pharma's case
The four-member committee charged with reviewing the World Health Organization’s report on Maiden Pharmaceuticals Ltd met for the first time. According to Union Health Ministry sources, the experts here discussed and expanded the investigation into the matter.
Piramal Pharma receives approval from SEBI to list shares on Indian stock exchanges
Piramal Pharma has been demerged from Piramal Enterprises Ltd (PEL) as part of the corporate structure simplification, following approval from the National Company Law Tribunal (NCLT). Sebi has sent a letter to Piramal Pharma and the company expects to list its shares on the Indian equity stock exchanges next week.
JB Pharma pledges to ESG in its initial Sustainability Report for SDG
J B Chemicals and Pharma published its first sustainability (ESG) report yesterday, prepared in accordance with the international reporting standards framework, with the Global Reporting Initiative (GRI) as its core standard and links to the Sustainable Development Goals (SDGs).
Novartis's prostate Cancer gets EMA recommendation over positive results in trial
Committe for Medicinal Products for Human Use
(CHMP), a part of the EMA has given its
recommendation to grant a marketing
authorization for the new prostate Cancer drug
“Pluvicto” by Novartis. The decision was based
on the data from the Phase III VISION study in
which the drug showed promising results.
